| Title: |
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting |
| Authors: |
Deschanvres, Colin; Reynes, Jacques; Lamaury, Isabelle; Rey, David; Palich, Romain; Bani-Sadr, Firouzé; Robineau, Olivier; Duvivier, Claudine; Hocqueloux, Laurent; Cuzin, Lise; Joly, Veronique; Raffi, Francois; Cabie, André; Allavena, Clotilde; Chirouze, C; Drobacheff-Thiébaut, C; Foltzer, A; Bouiller, K; Hustache- Mathieu, L; Lepiller, Q; Bozon, F; Babre, O; Brunel, A; Muret, P; Chevalier, E; Jacomet, C; Laurichesse, H; Lesens, O; Vidal, M; Mrozek, N; Aumeran, C; Baud, O; Corbin, V; Goncalvez, E; Mirand, A; Brebion, A; Henquell, C; Fabre, I; Curlier, E; Ouissa, R; Herrmann-Storck, C; Tressieres, B; Receveur, M; Boulard, F; Daniel, C; Clavel, C; Roger, P; Markowicz, S; Chellum Rungen, N; Merrien, D; Perré, P; Guimard, T; Bollangier, O; Leautez, S; Morrier, M; Laine, L; Boucher, D; Point, P; Cotte, L; Ader, F; Becker, A; Boibieux, A; Brochier, C; Brunel-Dalmas, F; Cannesson, O; Chiarello, P; Chidiac, C; Degroodt, S; Ferry, T; Godinot, M; Livrozet, J; Makhloufi, D; Miailhes, P; Perpoint, T; Perry, M; Pouderoux, C; Roux, S; Triffault-Fillit, C; Valour, F; Charre, C; Icard, V; Tardy, J; Trabaud, M; Ravaux, I; Ménard, A; Belkhir, A; Colson, P; Dhiver, C; Madrid, A; Martin-Degioanni, M; Meddeb, L; Mokhtari, M; Motte, A; Raoux, A; Toméi, C; Tissot-Dupont, H; Poizot-Martin, I; Brégigeon, S; Zaegel-Faucher, O; Obry-Roguet, V; Laroche, H; Orticoni, M; Soavi, M; Ressiot, E; Ducassou, M; Jaquet, I; Galie, S; Colson, H; Ritleng, A; Ivanova, A; Debreux, C; Lions, C; Rojas-Rojas, T; Abel, S; Bavay, J; Bigeard, B; Cabras, O; Dupin de Majoubert, R; Fagour, L; Guitteaud, K; Marquise, A; Najioullah, F; Pierre-François, S; Pasquier, J; Richard, P; Rome, K; Turmel, J; Varache, C; Atoui, N; Bistoquet, M; Delaporte, E; Le Moing, V; Makinson, A; Meftah, N; Merle de Boever, C; Montes, B; Montoya Ferrer, A; Tuaillon, E; Lefèvre, B; Jeanmaire, E; Hénard, S; Frentiu, E; Charmillon, A; Legoff, A; Tissot, N; André, M; Boyer, L; Bouillon, M; Delestan, M; Goehringer, F; Bevilacqua, S; Rabaud, C; May, T; Aubry, O; Billaud, E; Biron, C; Bonnet, B; Bouchez, S; Boutoille, D; Brunet-Cartier, C; Gaborit, B; Grégoire, A; Grégoire, M; Grossi, O; Guéry, R; Jovelin, T; Lefebvre, M; Le Turnier, P; Lecomte, R; Morineau, P; Reliquet, V; Sécher, S; Cavellec, M; Paredes, E; Soria, A; Ferré, V; André-Garnier, E; Rodallec, A; Pugliese, P; Breaud, S; Ceppi, C; Chirio, D; Cua, E; Dellamonica, P; Demonchy, E; de Monte, A; Durant, J; Etienne, C; Ferrando, S; Garraffo, R; Michelangeli, C; Mondain, V; Naqvi, A; Oran, N; Perbost, I; Carles, M; Klotz, C; Maka, A; Pradier, C; Prouvost-Keller, B; Risso, K; Rio, V; Rosenthal, E; Touitou, I; Wehrlen-Pugliese, S; Zouzou, G; Prazuck, T; Gubavu, C; Sève, A; Giaché, S; Rzepecki, V; Colin, M; Boulard, C; Thomas, G; Cheret, A; Goujard, C; Quertainmont, Y; Teicher, E; Lerolle, N; Jaureguiberry, S; Colarino, R; Deradji, O; Castro, A; Barrail-Tran, A; Yazdanpanah, Y; Landman, R; Ghosn, J; Rioux, C; Lariven, S; Gervais, A; Lescure, F; Matheron, S; Louni, F; Julia, Z; Le Gac, S; Charpentier, C; Descamps, D; Peytavin, G; Aguilar, C; Alby-Laurent, F; Amazzough, K; Benabdelmoumen, G; Bossi, P; Cessot, G; Charlier, C; Consigny, P; Jidar, K; Lafont, E; Lanternier, F; Leporrier, J; Lortholary, O; Louisin, C; Lourenco, J; Parize, P; Pilmis, B; Rouzaud, C; Touam, F; Valantin, M; Tubiana, R; Agher, R; Seang, S; Schneider, L; Blanc, C; Katlama, C; Berger, J; N’guyen, Y; Lambert, D; Kmiec, I; Hentzien, M; Brunet, A; Romaru, J; Marty, H; Brodard, V; Arvieux, C; Tattevin, P; Revest, M; Souala, F; Baldeyrou, M; Patrat-Delon, S; Chapplain, J; Benezit, F; Dupont, M; Poinot, M; Maillard, A; Pronier, C; Lemaitre, F; Morlat, C; Poisson-Vannier, M; Sinteff, J; Gagneux-Brunon, A; Botelho-Nevers, E; Frésard, A; Ronat, V; Lucht, F; Fischer, P; Partisani, M; Cheneau, C; Priester, M; Mélounou, C; Bernard-Henry, C; de Mautort, E; Fafi-Kremer, S; Delobel, Pierre; Alvarez, M; Biezunski, N; Debard, A; Delpierre, C; Gaube, G; Lansalot, P; Lelièvre, L; Marcel, M; Martin-Blondel, G; Piffaut, M; Porte, L; Saune, K; Ajana, F; Aïssi, E; Alcaraz, I; Alidjinou, E; Baclet, V; Bocket, L; Boucher, A; Digumber, M; Huleux, T; Lafon-Desmurs, B; Meybeck, A; Pradier, M; Tetart, M; Thill, P; Viget, N; Valette, M |
| Contributors: |
Service des maladies infectieuses et tropicales CHU Nantes; Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); Dat’AIDS Study Group; Département Maladies Infectieuses et Tropicales CHRU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI); Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM); CHU Pointe-à-Pitre / Abymes Guadeloupe; Hôpitaux Universitaires de Strasbourg (HUS); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Hôpital universitaire Robert Debré Reims (CHU Reims); Centre Hospitalier Gustave Dron Tourcoing; Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS); Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Institut Pasteur Paris (IP); Centre Hospitalier Regional d'Orléans (CHRO); Equipe EQUITY (CERPOP); Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP); Université Toulouse III - Paul Sabatier (UT3); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre Hospitalier Universitaire de Martinique Fort-de-France, Martinique (CHU de Martinique); AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Laboratoire Microorganismes : Génome et Environnement (LMGE); Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA); Université Clermont Auvergne (UCA); Service Hygiène Hospitalière CHU Clermont-Ferrand; Pôle RHEUNNIRS CHU Clermont-Ferrand; CHU Gabriel Montpied Clermont-Ferrand; CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied Clermont-Ferrand; CHU Clermont-Ferrand-CHU Clermont-Ferrand; CHU Clermont-Ferrand |
| Source: |
ISSN: 0305-7453. |
| Publisher Information: |
CCSD; Oxford University Press (OUP) |
| Publication Year: |
2022 |
| Collection: |
Université Toulouse III - Paul Sabatier: HAL-UPS |
| Subject Terms: |
MESH: Anti-HIV Agents; MESH: Emtricitabine; MESH: Piperazines; MESH: Pyridones; MESH: Rilpivirine; MESH: Viral Load; MESH: HIV Infections; MESH: Heterocyclic Compounds; 3-Ring; MESH: Humans; MESH: Lamivudine; MESH: Oxazines; [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases; [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences |
| Description: |
International audience ; Background Maintenance ART with dolutegravir-based dual regimens have proved their efficacy among HIV-1-infected subjects in randomized trials. However, real-life data are scarce, with limited populations and follow-up. Objectives We assessed virological failure (VF) and resistance-associated mutations (RAMs) on dolutegravir maintenance regimens in combination with rilpivirine or with lamivudine or emtricitabine (xTC) and analysed the factors associated with VF. Methods Between 2014 and 2018, all HIV-1-infected adults included in the Dat’AIDS cohort and starting dolutegravir/rilpivirine or dolutegravir/xTC as a maintenance dolutegravir-based dual regimen were selected. VF was defined as two consecutive HIV RNA values >50 copies/mL or a single value >400 copies/mL. We compared cumulative genotypes before initiation of a maintenance dolutegravir-based dual regimen with genotype at VF. Results We analysed 1374 subjects (799 on dolutegravir/rilpivirine and 575 on dolutegravir/xTC) with a median follow-up of 20 months (IQR = 11–31) and 19 months (IQR = 11–31), respectively. VF occurred in 3.8% (n = 30) of dolutegravir/rilpivirine subjects and 2.6% (n = 15) of dolutegravir/xTC subjects. Among subjects receiving dolutegravir/rilpivirine, two genotypes harboured emerging RAMs at VF: E138K on NNRTI (n = 1); and E138K+K101E on NNRTI and N155H on INSTI (n = 1). Among subjects receiving dolutegravir/xTC, no new RAM was detected. The only predictive factor of VF on dolutegravir/rilpivirine was the history of failure on an NNRTI-based regimen (adjusted HR = 2.97, 95% CI = 1.28–6.93). No factor was associated with VF on dolutegravir/xTC. Conclusions In this large real-life cohort, dolutegravir/rilpivirine and dolutegravir/xTC sustained virological suppression and were associated with a low rate of VF and RAM emergence. Careful virological screening is essential before switching to dolutegravir/rilpivirine in virologically suppressed patients with a history of NNRTI therapy. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/34651192; PUBMED: 34651192 |
| DOI: |
10.1093/jac/dkab367 |
| Availability: |
https://hal.science/hal-03640621; https://doi.org/10.1093/jac/dkab367 |
| Accession Number: |
edsbas.DD270C58 |
| Database: |
BASE |